Pharma Equity Group develops medicines for the treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The Company uses repositioning of existing medicines and takes drug candidates to a clinical Phase III stage, after which they are handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the Company.
PEG announced this morning that its subsidiary Reponex Pharmaceuticals has received a notification from the European Patent Office (EPO) of its intention to grant a European patent covering compositions and methods for the treatment of Inflammatory Bowel Disease (IBD).Strategically, the patent grant supports PEG's broader narrative of gradually de-risking its repositioning-based pipeline through a combination of clinical, commercial, and IP-related milestones
In connection with the publication of Pharma Equity Group's annual report for 2025, 2026 guidance and ongoing clinical developments, we have published our investment case.
Our investment case covers the key investment reasons and risks and valuation perspectives.
PEG's investment case centres on de-risking its pipeline through clinical progress and strategic partnerships, while diversifying into revenue-generating assets through its expanded Life Science consolidator strategy. The drug repositioning approach — repurposing previously approved active pharmaceutical ingredients for new therapeutic applications — aims to reduce clinical risk relative to de novo drug development, and the out-licensing model post-Phase II is designed to limit capital requirements and execution risk.
PEG maintained its guidance with its H1 2025 results, for DKK 11m in partner-driven revenue. The recent approval to initiate its RNX- 011 Phase IIb clinical trial strengthens PEG’s partner negotiation position.
